{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:15:08Z","timestamp":1791832508952,"version":"4.3.4"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s11302-022-09876-0","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T09:13:44Z","timestamp":1654766024000},"page":"253-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pleiotropic effects of clopidogrel"],"prefix":"10.1007","volume":"18","author":[{"given":"Dawn S.","family":"Kuszynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Adam","family":"Lauver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"9876_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1055\/s-0037-1615690","volume":"85","author":"C Dangelmaier","year":"2001","unstructured":"Dangelmaier C, Jin J, Smith JB, Kunapuli SP (2001) Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 85:341\u2013348. https:\/\/doi.org\/10.1055\/s-0037-1615690","journal-title":"Thromb Haemost"},{"key":"9876_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.crci.2012.05.006","volume":"15","author":"J-P Maffrand","year":"2012","unstructured":"Maffrand J-P (2012) The story of clopidogrel and its predecessor, ticlopidine: could these major antiplatelet and antithrombotic drugs be discovered and developed today? C R Chim 15:737\u2013743. https:\/\/doi.org\/10.1016\/j.crci.2012.05.006","journal-title":"C R Chim"},{"key":"9876_CR3","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1055\/s-0038-1653424","volume":"46","author":"H Lee","year":"1981","unstructured":"Lee H, Paton RC, Ruan C, Caen JP (1981) The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets. Thromb Haemost 46:590\u2013592","journal-title":"Thromb Haemost"},{"key":"9876_CR4","first-page":"772","volume":"269","author":"P Savi","year":"1994","unstructured":"Savi P, Laplace MC, Maffrand JP, Herbert JM (1994) Binding of [3H]-2-methylthio ADP to rat platelets\u2013effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 269:772\u2013777","journal-title":"J Pharmacol Exp Ther"},{"key":"9876_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/01.atv.12.4.430","volume":"12","author":"DC Mills","year":"1992","unstructured":"Mills DC, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD et al (1992) Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 12:430\u2013436. https:\/\/doi.org\/10.1161\/01.atv.12.4.430","journal-title":"Arterioscler Thromb"},{"key":"9876_CR6","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/0006-2952(88)90246-8","volume":"37","author":"R Feliste","year":"1988","unstructured":"Feliste R, Simon MF, Chap H, Douste-Blazy L, Defreyn G, Maffrand JP (1988) Effect of PCR 4099 on ADP-induced calcium movements and phosphatidic acid production in rat platelets. Biochem Pharmacol 37:2559\u20132564. https:\/\/doi.org\/10.1016\/0006-2952(88)90246-8","journal-title":"Biochem Pharmacol"},{"key":"9876_CR7","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1016\/0006-2952(90)90587-b","volume":"40","author":"C Gachet","year":"1990","unstructured":"Gachet C, Cazenave JP, Ohlmann P, Bouloux C, Defreyn G, Driot F et al (1990) The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem Pharmacol 40:2683\u20132687. https:\/\/doi.org\/10.1016\/0006-2952(90)90587-b","journal-title":"Biochem Pharmacol"},{"key":"9876_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0049-3848(87)90398-7","volume":"48","author":"R F\u00e9liste","year":"1987","unstructured":"F\u00e9liste R, Delebass\u00e9e D, Simon MF, Chap H, Defreyn G, Vall\u00e9e E et al (1987) Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res 48:403\u2013415. https:\/\/doi.org\/10.1016\/0049-3848(87)90398-7","journal-title":"Thromb Res"},{"key":"9876_CR9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1055\/s-0038-1647481","volume":"65","author":"G Defreyn","year":"1991","unstructured":"Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP, Maffrand JP (1991) Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 65:186\u2013190. https:\/\/doi.org\/10.1055\/s-0038-1647481","journal-title":"Thromb Haemost"},{"key":"9876_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0006-2952(90)90683-c","volume":"40","author":"C Gachet","year":"1990","unstructured":"Gachet C, Stierl\u00e9 A, Cazenave JP, Ohlmann P, Lanza F, Bouloux C et al (1990) The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 40:229\u2013238. https:\/\/doi.org\/10.1016\/0006-2952(90)90683-c","journal-title":"Biochem Pharmacol"},{"key":"9876_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0049-3848(87)90390-2","volume":"48","author":"J Damas","year":"1987","unstructured":"Damas J, Grek V, Remacle-Volon G (1987) Inhibition of the thrombocytopenic effect of exogenous and endogenous thrombin by PCR 4099 (d,1)methyl 2-(2-chlorophenyl)-2(4,5,6, 7-tetrahydrothieno (3,2-c)pyridin-5-yl) acetate.hydrochloride.monohydrate. Thromb Res 48:585\u2013589. https:\/\/doi.org\/10.1016\/0049-3848(87)90390-2","journal-title":"Thromb Res"},{"key":"9876_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/35051599","volume":"409","author":"G Hollopeter","year":"2001","unstructured":"Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V et al (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202\u2013207. https:\/\/doi.org\/10.1038\/35051599","journal-title":"Nature"},{"key":"9876_CR13","first-page":"432","volume":"60","author":"J Takasaki","year":"2001","unstructured":"Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T et al (2001) Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol 60:432\u2013439","journal-title":"Mol Pharmacol"},{"key":"9876_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1006\/bbrc.2001.4816","volume":"283","author":"P Savi","year":"2001","unstructured":"Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM (2001) P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283:379\u2013383. https:\/\/doi.org\/10.1006\/bbrc.2001.4816","journal-title":"Biochem Biophys Res Commun"},{"key":"9876_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2165\/00003495-199754050-00006","volume":"54","author":"AJ Coukell","year":"1997","unstructured":"Coukell AJ, Markham A (1997) Clopidogrel. Drugs 54:745\u201350. https:\/\/doi.org\/10.2165\/00003495-199754050-00006 (discussion 751)","journal-title":"Drugs"},{"key":"9876_CR16","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1182\/blood-2002-10-3027","volume":"101","author":"Z Ding","year":"2003","unstructured":"Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP (2003) Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101:3908\u20133914. https:\/\/doi.org\/10.1182\/blood-2002-10-3027","journal-title":"Blood"},{"key":"9876_CR17","unstructured":"Drug Approval Package: Plavix\/Clopidogrel bisulfate NDA 20839. [cited 2 Jun 2022]. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/020839_plavix_toc.cfm"},{"key":"9876_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1055\/s-0037-1614133","volume":"84","author":"P Savi","year":"2000","unstructured":"Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP et al (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891\u2013896. https:\/\/doi.org\/10.1055\/s-0037-1614133","journal-title":"Thromb Haemost"},{"key":"9876_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nm.2281","volume":"17","author":"HJ Bouman","year":"2011","unstructured":"Bouman HJ, Sch\u00f6mig E, van Werkum JW, Velder J, Hackeng CM, Hirschh\u00e4user C et al (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17:110\u2013116. https:\/\/doi.org\/10.1038\/nm.2281","journal-title":"Nat Med"},{"key":"9876_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00216-011-5147-4","volume":"401","author":"L Silvestro","year":"2011","unstructured":"Silvestro L, Gheorghe M, Iordachescu A, Ciuca V, Tudoroniu A, Rizea Savu S et al (2011) Development and validation of an HPLC-MS\/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. Anal Bioanal Chem 401:1023\u20131034. https:\/\/doi.org\/10.1007\/s00216-011-5147-4","journal-title":"Anal Bioanal Chem"},{"issue":"Suppl 2","key":"9876_CR21","first-page":"29","volume":"25","author":"R Lins","year":"1999","unstructured":"Lins R, Broekhuysen J, Necciari J, Deroubaix X (1999) Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost 25(Suppl 2):29\u201333","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 2","key":"9876_CR22","first-page":"25","volume":"25","author":"H Caplain","year":"1999","unstructured":"Caplain H, Donat F, Gaud C, Necciari J (1999) Pharmacokinetics of clopidogrel. Semin Thromb Hemost 25(Suppl 2):25\u201328","journal-title":"Semin Thromb Hemost"},{"key":"9876_CR23","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1124\/dmd.109.028498","volume":"37","author":"K Hagihara","year":"2009","unstructured":"Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O et al (2009) A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 37:2145\u20132152. https:\/\/doi.org\/10.1124\/dmd.109.028498","journal-title":"Drug Metab Dispos"},{"key":"9876_CR24","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1124\/jpet.106.110577","volume":"319","author":"M Tang","year":"2006","unstructured":"Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C et al (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467\u20131476. https:\/\/doi.org\/10.1124\/jpet.106.110577","journal-title":"J Pharmacol Exp Ther"},{"key":"9876_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.acvd.2013.09.002","volume":"106","author":"C Funck-Brentano","year":"2013","unstructured":"Funck-Brentano C, Szymezak J, Steichen O, Ducint D, Molimard M, Remones V et al (2013) Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Arch Cardiovasc Dis 106:661\u2013671. https:\/\/doi.org\/10.1016\/j.acvd.2013.09.002","journal-title":"Arch Cardiovasc Dis"},{"key":"9876_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jcpt.12254","volume":"40","author":"R Lin","year":"2015","unstructured":"Lin R, Zhang L, Zhang P, Zhou L, Liu T, Li Y et al (2015) Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China. J Clin Pharm Ther 40:308\u2013314. https:\/\/doi.org\/10.1111\/jcpt.12254","journal-title":"J Clin Pharm Ther"},{"key":"9876_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","volume":"316","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y et al (2016) Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 316:70\u201378. https:\/\/doi.org\/10.1001\/jama.2016.8662","journal-title":"JAMA"},{"key":"9876_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cca.2012.11.022","volume":"416","author":"H Zhou","year":"2013","unstructured":"Zhou H, Meng S, Zhao J, Dong J, Xu A, Wang F et al (2013) Influence of genetic and non-genetic factors on the plasma concentrations of the clopidogrel metabolite (SR26334) among Chinese patients. Clin Chim Acta 416:50\u201353. https:\/\/doi.org\/10.1016\/j.cca.2012.11.022","journal-title":"Clin Chim Acta"},{"key":"9876_CR29","unstructured":"FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug | FDA. [cited 29 Nov 2021]. Available: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor"},{"key":"9876_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/clpt.2010.219","volume":"89","author":"DJ Angiolillo","year":"2011","unstructured":"Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L et al (2011) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89:65\u201374. https:\/\/doi.org\/10.1038\/clpt.2010.219","journal-title":"Clin Pharmacol Ther"},{"key":"9876_CR31","doi-asserted-by":"publisher","first-page":"119268","DOI":"10.1016\/j.lfs.2021.119268","volume":"279","author":"P-X Ge","year":"2021","unstructured":"Ge P-X, Jiang L-P, Tai T, Zhu T, Ji J-Z, Li Y-F et al (2021) Short-term standard alcohol consumption enhances platelet response to clopidogrel through inhibition of Nrf2\/Ces1 pathway and induction of Cyp2c in mice. Life Sci 279:119268. https:\/\/doi.org\/10.1016\/j.lfs.2021.119268","journal-title":"Life Sci"},{"key":"9876_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/00498254.2019.1612535","volume":"50","author":"SC Laizure","year":"2020","unstructured":"Laizure SC, Hu Z-Y, Potter PM, Parker RB (2020) Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. Xenobiotica 50:245\u2013251. https:\/\/doi.org\/10.1080\/00498254.2019.1612535","journal-title":"Xenobiotica"},{"key":"9876_CR33","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.jacc.2011.11.068","volume":"59","author":"MJ Price","year":"2012","unstructured":"Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL et al (2012) Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (genotype information and functional testing) study. J Am Coll Cardiol 59:1928\u20131937. https:\/\/doi.org\/10.1016\/j.jacc.2011.11.068","journal-title":"J Am Coll Cardiol"},{"key":"9876_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","volume":"64","author":"DJ Angiolillo","year":"2014","unstructured":"Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F et al (2014) Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 64:1005\u20131014. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1170","journal-title":"J Am Coll Cardiol"},{"key":"9876_CR35","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.jacc.2008.07.068","volume":"52","author":"D Erlinge","year":"2008","unstructured":"Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA et al (2008) Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 52:1968\u20131977. https:\/\/doi.org\/10.1016\/j.jacc.2008.07.068","journal-title":"J Am Coll Cardiol"},{"key":"9876_CR36","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/ATVBAHA.120.314146","volume":"40","author":"Y Sun","year":"2020","unstructured":"Sun Y, Venugopal J, Guo C, Fan Y, Li J, Gong Y et al (2020) Clopidogrel resistance in a murine model of diet-induced obesity is mediated by the interleukin -1 receptor and overcome with DT-678. Arterioscler Thromb Vasc Biol 40:1533\u20131542. https:\/\/doi.org\/10.1161\/ATVBAHA.120.314146","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9876_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","volume":"122","author":"M Koupenova","year":"2018","unstructured":"Koupenova M, Clancy L, Corkrey HA, Freedman JE (2018) Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res 122:337\u2013351. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310795","journal-title":"Circ Res"},{"key":"9876_CR38","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK et al (2017) A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169:1276-1290.e17. https:\/\/doi.org\/10.1016\/j.cell.2017.05.018","journal-title":"Cell"},{"key":"9876_CR39","doi-asserted-by":"publisher","first-page":"239821281881749","DOI":"10.1177\/2398212818817494","volume":"2","author":"G Burnstock","year":"2018","unstructured":"Burnstock G (2018) Purine and purinergic receptors. Brain Neurosci Adv 2:239821281881749. https:\/\/doi.org\/10.1177\/2398212818817494","journal-title":"Brain Neurosci Adv"},{"key":"9876_CR40","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.coph.2010.01.003","volume":"10","author":"IR Orriss","year":"2010","unstructured":"Orriss IR, Burnstock G, Arnett TR (2010) Purinergic signalling and bone remodelling. Curr Opin Pharmacol 10:322\u2013330. https:\/\/doi.org\/10.1016\/j.coph.2010.01.003","journal-title":"Curr Opin Pharmacol"},{"key":"9876_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00418-011-0859-2","volume":"136","author":"K Uehara","year":"2011","unstructured":"Uehara K, Uehara A (2011) P2Y1, P2Y6, and P2Y12 receptors in rat splenic sinus endothelial cells: an immunohistochemical and ultrastructural study. Histochem Cell Biol 136:557\u2013567. https:\/\/doi.org\/10.1007\/s00418-011-0859-2","journal-title":"Histochem Cell Biol"},{"key":"9876_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/FJC.0000000000000866","volume":"76","author":"AM Gdula","year":"2020","unstructured":"Gdula AM, Swiatkowska M (2020) Effects of dual purinoceptor-dependent approach on release of vascular endothelial growth factor from human microvascular endothelial cell (HMEC-1) and endothelial cell condition. J Cardiovasc Pharmacol 76:349\u2013359. https:\/\/doi.org\/10.1097\/FJC.0000000000000866","journal-title":"J Cardiovasc Pharmacol"},{"key":"9876_CR43","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s11239-020-02098-4","volume":"50","author":"F Li","year":"2020","unstructured":"Li F, Xu D, Hou K, Gou X, Li Y (2020) The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells. J Thromb Thrombolysis 50:874\u2013885. https:\/\/doi.org\/10.1007\/s11239-020-02098-4","journal-title":"J Thromb Thrombolysis"},{"key":"9876_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCRESAHA.116.309726","volume":"120","author":"G Burnstock","year":"2017","unstructured":"Burnstock G (2017) Purinergic signaling in the cardiovascular system. Circ Res 120:207\u2013228. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.309726","journal-title":"Circ Res"},{"key":"9876_CR45","unstructured":"Tissue expression of P2RY12 - summary - the Human Protein Atlas. [cited 29 Nov 2021]. Available: https:\/\/www.proteinatlas.org\/ENSG00000169313-P2RY12\/tissue"},{"key":"9876_CR46","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","volume":"420","author":"P Libby","year":"2002","unstructured":"Libby P (2002) Inflammation in atherosclerosis. Nature 420:868\u2013874. https:\/\/doi.org\/10.1038\/nature01323","journal-title":"Nature"},{"key":"9876_CR47","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","volume":"47","author":"E Falk","year":"2006","unstructured":"Falk E (2006) Pathogenesis of atherosclerosis. J Am Coll Cardiol 47:C7-12. https:\/\/doi.org\/10.1016\/j.jacc.2005.09.068","journal-title":"J Am Coll Cardiol"},{"key":"9876_CR48","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00380-015-0696-7","volume":"31","author":"C Heim","year":"2016","unstructured":"Heim C, Gebhardt J, Ramsperger-Gleixner M, Jacobi J, Weyand M, Ensminger SM (2016) Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. Heart Vessels 31:783\u2013794. https:\/\/doi.org\/10.1007\/s00380-015-0696-7","journal-title":"Heart Vessels"},{"key":"9876_CR49","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.atherosclerosis.2006.11.006","volume":"194","author":"M Li","year":"2007","unstructured":"Li M, Zhang Y, Ren H, Zhang Y, Zhu X (2007) Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis 194:348\u2013356. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.11.006","journal-title":"Atherosclerosis"},{"key":"9876_CR50","doi-asserted-by":"publisher","first-page":"e0218934","DOI":"10.1371\/journal.pone.0218934","volume":"14","author":"H Halim","year":"2019","unstructured":"Halim H, Pinkaew D, Chunhacha P, Sinthujaroen P, Thiagarajan P, Fujise K (2019) Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel. PLoS ONE 14:e0218934. https:\/\/doi.org\/10.1371\/journal.pone.0218934","journal-title":"PLoS ONE"},{"key":"9876_CR51","doi-asserted-by":"publisher","DOI":"10.3233\/CH-211279","author":"J Zhang","year":"2021","unstructured":"Zhang J, Shi Q, Hu Y, Li X (2021) Silibinin augments the effect of clopidogrel on atherosclerosis in diabetic ApoE deficiency mice. Clin Hemorheol Microcirc. https:\/\/doi.org\/10.3233\/CH-211279","journal-title":"Clin Hemorheol Microcirc"},{"key":"9876_CR52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1161\/CIRCULATIONAHA.107.762690","volume":"119","author":"DJW Evans","year":"2009","unstructured":"Evans DJW, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K et al (2009) Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 119:116\u2013122. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.762690","journal-title":"Circulation"},{"issue":"Suppl 1","key":"9876_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1538-7836.2007.02517.x","volume":"5","author":"S Lindemann","year":"2007","unstructured":"Lindemann S, Kr\u00e4mer B, Seizer P, Gawaz M (2007) Platelets, inflammation and atherosclerosis. J Thromb Haemost 5(Suppl 1):203\u2013211. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02517.x","journal-title":"J Thromb Haemost"},{"key":"9876_CR54","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1161\/01.cir.98.12.1164","volume":"98","author":"M Gawaz","year":"1998","unstructured":"Gawaz M, Neumann FJ, Dickfeld T, Koch W, Laugwitz KL, Adelsberger H et al (1998) Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 98:1164\u20131171. https:\/\/doi.org\/10.1161\/01.cir.98.12.1164","journal-title":"Circulation"},{"key":"9876_CR55","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1172\/JCI11871","volume":"107","author":"MI Cybulsky","year":"2001","unstructured":"Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M et al (2001) A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107:1255\u20131262. https:\/\/doi.org\/10.1172\/JCI11871","journal-title":"J Clin Invest"},{"key":"9876_CR56","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/clc.22575","volume":"39","author":"M Oh","year":"2016","unstructured":"Oh M, Lee CW, Lee HS, Chang M, Ahn J-M, Park D-W et al (2016) Similar impact of clopidogrel or ticagrelor on carotid atherosclerotic plaque inflammation. Clin Cardiol 39:646\u2013652. https:\/\/doi.org\/10.1002\/clc.22575","journal-title":"Clin Cardiol"},{"key":"9876_CR57","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1194\/jlr.R067249","volume":"57","author":"GS Getz","year":"2016","unstructured":"Getz GS, Reardon CA (2016) ApoE knockout and knockin mice: the history of their contribution to the understanding of atherogenesis. J Lipid Res 57:758\u2013766. https:\/\/doi.org\/10.1194\/jlr.R067249","journal-title":"J Lipid Res"},{"key":"9876_CR58","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/cvr\/cvu028","volume":"102","author":"LE West","year":"2014","unstructured":"West LE, Steiner T, Judge HM, Francis SE, Storey RF (2014) Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovasc Res 102:429\u2013435. https:\/\/doi.org\/10.1093\/cvr\/cvu028","journal-title":"Cardiovasc Res"},{"key":"9876_CR59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.phrs.2017.03.017","volume":"120","author":"VC Biancardi","year":"2017","unstructured":"Biancardi VC, Bomfim GF, Reis WL, Al-Gassimi S, Nunes KP (2017) The interplay between angiotensin II, TLR4 and hypertension. Pharmacol Res 120:88\u201396. https:\/\/doi.org\/10.1016\/j.phrs.2017.03.017","journal-title":"Pharmacol Res"},{"key":"9876_CR60","doi-asserted-by":"publisher","first-page":"e009600","DOI":"10.1161\/JAHA.118.009600","volume":"7","author":"X An","year":"2018","unstructured":"An X, Jiang G, Cheng C, Lv Z, Liu Y, Wang F (2018) Inhibition of platelets by clopidogrel suppressed Ang II-Induced Vascular Inflammation, Oxidative Stress, and Remodeling. J Am Heart Assoc 7:e009600. https:\/\/doi.org\/10.1161\/JAHA.118.009600","journal-title":"J Am Heart Assoc"},{"key":"9876_CR61","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1042\/CS20090392","volume":"118","author":"FRC Giachini","year":"2010","unstructured":"Giachini FRC, Osmond DA, Zhang S, Carneiro FS, Lima VV, Inscho EW et al (2010) Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats. Clin Sci 118:463\u2013471. https:\/\/doi.org\/10.1042\/CS20090392","journal-title":"Clin Sci"},{"key":"9876_CR62","doi-asserted-by":"publisher","first-page":"e91890","DOI":"10.1371\/journal.pone.0091890","volume":"9","author":"FR Giachini","year":"2014","unstructured":"Giachini FR, Leite R, Osmond DA, Lima VV, Inscho EW, Webb RC et al (2014) Anti-platelet therapy with clopidogrel prevents endothelial dysfunction and vascular remodeling in aortas from hypertensive rats. PLoS ONE 9:e91890. https:\/\/doi.org\/10.1371\/journal.pone.0091890","journal-title":"PLoS ONE"},{"key":"9876_CR63","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1089\/ars.2012.5149","volume":"20","author":"M Mittal","year":"2014","unstructured":"Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB (2014) Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 20:1126\u20131167. https:\/\/doi.org\/10.1089\/ars.2012.5149","journal-title":"Antioxid Redox Signal"},{"issue":"Suppl 1","key":"9876_CR64","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1007\/s10620-005-2803-6","volume":"50","author":"AS Tarnawski","year":"2005","unstructured":"Tarnawski AS (2005) Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 50(Suppl 1):S24-33. https:\/\/doi.org\/10.1007\/s10620-005-2803-6","journal-title":"Dig Dis Sci"},{"issue":"Suppl 4","key":"9876_CR65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/jgh.12734","volume":"29","author":"AS Tarnawski","year":"2014","unstructured":"Tarnawski AS, Ahluwalia A, Jones MK (2014) Angiogenesis in gastric mucosa: an important component of gastric erosion and ulcer healing and its impairment in aging. J Gastroenterol Hepatol 29(Suppl 4):112\u2013123. https:\/\/doi.org\/10.1111\/jgh.12734","journal-title":"J Gastroenterol Hepatol"},{"key":"9876_CR66","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jfma.2015.07.022","volume":"115","author":"J-C Luo","year":"2016","unstructured":"Luo J-C, Peng Y-L, Chen T-S, Huo T-I, Hou M-C, Huang H-C et al (2016) Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. J Formos Med Assoc 115:764\u2013772. https:\/\/doi.org\/10.1016\/j.jfma.2015.07.022","journal-title":"J Formos Med Assoc"},{"key":"9876_CR67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0014-5793(04)00108-5","volume":"561","author":"S Ludwig","year":"2004","unstructured":"Ludwig S, Wolff T, Ehrhardt C, Wurzer WJ, Reinhardt J, Planz O et al (2004) MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett 561:37\u201343. https:\/\/doi.org\/10.1016\/S0014-5793(04)00108-5","journal-title":"FEBS Lett"},{"key":"9876_CR68","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/35060098","volume":"3","author":"S Pleschka","year":"2001","unstructured":"Pleschka S, Wolff T, Ehrhardt C, Hobom G, Planz O, Rapp UR et al (2001) Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade. Nat Cell Biol 3:301\u2013305. https:\/\/doi.org\/10.1038\/35060098","journal-title":"Nat Cell Biol"},{"key":"9876_CR69","doi-asserted-by":"publisher","unstructured":"Orr-Burks N, Murray J, Todd KV, Bakre A, Tripp RA. (2021) G-protein-coupled receptor and ion channel genes used by influenza virus for replication. J Virol. 95. https:\/\/doi.org\/10.1128\/JVI.02410-20","DOI":"10.1128\/JVI.02410-20"},{"key":"9876_CR70","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1515\/BC.2008.145","volume":"389","author":"S Pleschka","year":"2008","unstructured":"Pleschka S (2008) RNA viruses and the mitogenic Raf\/MEK\/ERK signal transduction cascade. Biol Chem 389:1273\u20131282. https:\/\/doi.org\/10.1515\/BC.2008.145","journal-title":"Biol Chem"},{"key":"9876_CR71","doi-asserted-by":"publisher","first-page":"e0259129","DOI":"10.1371\/journal.pone.0259129","volume":"16","author":"N Orr-Burks","year":"2021","unstructured":"Orr-Burks N, Murray J, Todd KV, Bakre A, Tripp RA (2021) Drug repositioning of clopidogrel or triamterene to inhibit influenza virus replication in vitro. PLoS ONE 16:e0259129. https:\/\/doi.org\/10.1371\/journal.pone.0259129","journal-title":"PLoS ONE"},{"key":"9876_CR72","doi-asserted-by":"publisher","unstructured":"Degirmenci U, Wang M, Hu J (2020) Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy. Cells 9 https:\/\/doi.org\/10.3390\/cells9010198","DOI":"10.3390\/cells9010198"},{"key":"9876_CR73","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","volume":"109","author":"V Asati","year":"2016","unstructured":"Asati V, Mahapatra DK, Bharti SK (2016) PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem 109:314\u2013341. https:\/\/doi.org\/10.1016\/j.ejmech.2016.01.012","journal-title":"Eur J Med Chem"},{"key":"9876_CR74","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/jb\/mvr079","volume":"150","author":"K Suzuki-Inoue","year":"2011","unstructured":"Suzuki-Inoue K (2011) Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation. J Biochem 150:127\u2013132. https:\/\/doi.org\/10.1093\/jb\/mvr079","journal-title":"J Biochem"},{"key":"9876_CR75","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1124\/jpet.105.098384","volume":"317","author":"C Medina","year":"2006","unstructured":"Medina C, Jurasz P, Santos-Martinez MJ, Jeong SS, Mitsky T, Chen R et al (2006) Platelet aggregation-induced by caco-2 cells: regulation by matrix metalloproteinase-2 and adenosine diphosphate. J Pharmacol Exp Ther 317:739\u2013745. https:\/\/doi.org\/10.1124\/jpet.105.098384","journal-title":"J Pharmacol Exp Ther"},{"key":"9876_CR76","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00109-013-1074-5","volume":"91","author":"S Danckwardt","year":"2013","unstructured":"Danckwardt S, Hentze MW, Kulozik AE (2013) Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med 91:1257\u20131271. https:\/\/doi.org\/10.1007\/s00109-013-1074-5","journal-title":"J Mol Med"},{"key":"9876_CR77","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.pmbts.2017.01.002","volume":"147","author":"P Gresele","year":"2017","unstructured":"Gresele P, Falcinelli E, Sebastiano M, Momi S (2017) Matrix metalloproteinases and platelet function. Prog Mol Biol Transl Sci 147:133\u2013165. https:\/\/doi.org\/10.1016\/bs.pmbts.2017.01.002","journal-title":"Prog Mol Biol Transl Sci"},{"key":"9876_CR78","doi-asserted-by":"publisher","first-page":"e0188740","DOI":"10.1371\/journal.pone.0188740","volume":"12","author":"A Denslow","year":"2017","unstructured":"Denslow A, \u015awitalska M, Jarosz J, Papiernik D, Porshneva K, Nowak M et al (2017) Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: studies in animal models. PLoS ONE 12:e0188740. https:\/\/doi.org\/10.1371\/journal.pone.0188740","journal-title":"PLoS ONE"},{"key":"9876_CR79","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1021\/acs.molpharmaceut.8b00781","volume":"15","author":"K Porshneva","year":"2018","unstructured":"Porshneva K, Papiernik D, Psurski M, Nowak M, Matkowski R, Ekiert M et al (2018) Combination therapy with DETA\/NO and clopidogrel inhibits metastasis in murine mammary gland cancer models via improved vasoprotection. Mol Pharm 15:5277\u20135290. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00781","journal-title":"Mol Pharm"},{"key":"9876_CR80","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.cgh.2018.12.012","volume":"17","author":"A Rodr\u00edguez-Miguel","year":"2019","unstructured":"Rodr\u00edguez-Miguel A, Garc\u00eda-Rodr\u00edguez LA, Gil M, Montoya H, Rodr\u00edguez-Mart\u00edn S, de Abajo FJ (2019) Clopidogrel and low-dose aspirin, alone or together, reduce risk of colorectal cancer. Clin Gastroenterol Hepatol 17:2024-2033.e2. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9876_CR81","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.amjmed.2017.01.022","volume":"130","author":"A Leader","year":"2017","unstructured":"Leader A, Zelikson-Saporta R, Pereg D, Spectre G, Rozovski U, Raanani P et al (2017) The effect of combined aspirin and clopidogrel treatment on cancer incidence. Am J Med 130:826\u2013832. https:\/\/doi.org\/10.1016\/j.amjmed.2017.01.022","journal-title":"Am J Med"},{"key":"9876_CR82","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1002\/jbmr.1690","volume":"27","author":"S Syberg","year":"2012","unstructured":"Syberg S, Brandao-Burch A, Patel JJ, Hajjawi M, Arnett TR, Schwarz P et al (2012) Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. J Bone Miner Res 27:2373\u20132386. https:\/\/doi.org\/10.1002\/jbmr.1690","journal-title":"J Bone Miner Res"},{"key":"9876_CR83","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1096\/fj.201600616R","volume":"30","author":"A Mediero","year":"2016","unstructured":"Mediero A, Wilder T, Reddy VSR, Cheng Q, Tovar N, Coelho PG et al (2016) Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism. FASEB J 30:3887\u20133900. https:\/\/doi.org\/10.1096\/fj.201600616R","journal-title":"FASEB J"},{"key":"9876_CR84","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5312\/wjo.v10.i12.434","volume":"10","author":"T Lillis","year":"2019","unstructured":"Lillis T, Veis A, Sakellaridis N, Tsirlis A, Dailiana Z (2019) Effect of clopidogrel in bone healing-experimental study in rabbits. World J Orthop 10:434\u2013445. https:\/\/doi.org\/10.5312\/wjo.v10.i12.434","journal-title":"World J Orthop"},{"key":"9876_CR85","doi-asserted-by":"publisher","unstructured":"Nelson TA, Parker WAE, Ghukasyan Lakic T, Westerbergh J, James SK, Siegbahn A, et al. (2021) Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets. 1\u20137 https:\/\/doi.org\/10.1080\/09537104.2021.1934667","DOI":"10.1080\/09537104.2021.1934667"},{"key":"9876_CR86","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0023677215570087","volume":"49","author":"K Hamesch","year":"2015","unstructured":"Hamesch K, Borkham-Kamphorst E, Strnad P, Weiskirchen R (2015) Lipopolysaccharide-induced inflammatory liver injury in mice. Lab Anim 49:37\u201346. https:\/\/doi.org\/10.1177\/0023677215570087","journal-title":"Lab Anim"},{"key":"9876_CR87","doi-asserted-by":"publisher","unstructured":"Liu T, Zhang L, Joo D, Sun S-C. (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2 https:\/\/doi.org\/10.1038\/sigtrans.2017.23","DOI":"10.1038\/sigtrans.2017.23"},{"key":"9876_CR88","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12872-019-01287-1","volume":"19","author":"Z Jia","year":"2019","unstructured":"Jia Z, Huang Y, Ji X, Sun J, Fu G (2019) Ticagrelor and clopidogrel suppress NF-\u03baB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells. BMC Cardiovasc Disord 19:318. https:\/\/doi.org\/10.1186\/s12872-019-01287-1","journal-title":"BMC Cardiovasc Disord"},{"key":"9876_CR89","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/SHK.0b013e3181f48987","volume":"35","author":"S Hagiwara","year":"2011","unstructured":"Hagiwara S, Iwasaka H, Hasegawa A, Oyama M, Imatomi R, Uchida T et al (2011) Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 35:289\u2013292. https:\/\/doi.org\/10.1097\/SHK.0b013e3181f48987","journal-title":"Shock"},{"key":"9876_CR90","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1189\/jlb.1012518","volume":"95","author":"E Liverani","year":"2014","unstructured":"Liverani E, Rico MC, Yaratha L, Tsygankov AY, Kilpatrick LE, Kunapuli SP (2014) LPS-induced systemic inflammation is more severe in P2Y12 null mice. J Leukoc Biol 95:313\u2013323. https:\/\/doi.org\/10.1189\/jlb.1012518","journal-title":"J Leukoc Biol"},{"key":"9876_CR91","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","volume":"35","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Outteridge SN, Ajjan RA, Phoenix F, Sangha GK, Faulkner RE et al (2015) Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model. Arterioscler Thromb Vasc Biol 35:2562\u20132570. https:\/\/doi.org\/10.1161\/ATVBAHA.115.306528","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"9876_CR92","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11239-007-0026-8","volume":"24","author":"LA Malek","year":"2007","unstructured":"Malek LA, Grabowski M, Spiewak M, Filipiak KJ, Szpotanska M, Imiela T et al (2007) Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. J Thromb Thrombolysis 24:301\u2013305. https:\/\/doi.org\/10.1007\/s11239-007-0026-8","journal-title":"J Thromb Thrombolysis"},{"key":"9876_CR93","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/sj.bjp.0705186","volume":"138","author":"A-K Wihlborg","year":"2003","unstructured":"Wihlborg A-K, Malmsj\u00f6 M, Eyjolfsson A, Gustafsson R, Jacobson K, Erlinge D (2003) Extracellular nucleotides induce vasodilatation in human arteries via prostaglandins, nitric oxide and endothelium-derived hyperpolarising factor. Br J Pharmacol 138:1451\u20131458. https:\/\/doi.org\/10.1038\/sj.bjp.0705186","journal-title":"Br J Pharmacol"},{"key":"9876_CR94","doi-asserted-by":"publisher","first-page":"e108782","DOI":"10.1371\/journal.pone.0108782","volume":"9","author":"KA Haanes","year":"2014","unstructured":"Haanes KA, Edvinsson L (2014) Expression and characterization of purinergic receptors in rat middle meningeal artery-potential role in migraine. PLoS ONE 9:e108782. https:\/\/doi.org\/10.1371\/journal.pone.0108782","journal-title":"PLoS ONE"},{"key":"9876_CR95","doi-asserted-by":"publisher","first-page":"174545","DOI":"10.1016\/j.ejphar.2021.174545","volume":"911","author":"DS Kuszynski","year":"2021","unstructured":"Kuszynski DS, Christian BD, Dorrance AM, Lauver DA (2021) Clopidogrel treatment inhibits P2Y2-mediated constriction in the rabbit middle cerebral artery. Eur J Pharmacol 911:174545. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174545","journal-title":"Eur J Pharmacol"},{"key":"9876_CR96","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijcard.2008.12.091","volume":"142","author":"C H\u00f6gberg","year":"2010","unstructured":"H\u00f6gberg C, Svensson H, Gustafsson R, Eyjolfsson A, Erlinge D (2010) The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol 142:187\u2013192. https:\/\/doi.org\/10.1016\/j.ijcard.2008.12.091","journal-title":"Int J Cardiol"},{"key":"9876_CR97","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.plefa.2004.10.011","volume":"72","author":"A Jakubowski","year":"2005","unstructured":"Jakubowski A, Chlopicki S, Olszanecki R, Jawien J, Lomnicka M, Dupin JP et al (2005) Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins Leukot Essent Fatty Acids 72:139\u2013145. https:\/\/doi.org\/10.1016\/j.plefa.2004.10.011","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"9876_CR98","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.thromres.2011.12.029","volume":"130","author":"G Grzesk","year":"2012","unstructured":"Grzesk G, Kozinski M, Navarese EP, Krzyzanowski M, Grzesk E, Kubica A et al (2012) Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res 130:65\u201369. https:\/\/doi.org\/10.1016\/j.thromres.2011.12.029","journal-title":"Thromb Res"},{"key":"9876_CR99","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.2042-7158.2011.01313.x","volume":"63","author":"G Froldi","year":"2011","unstructured":"Froldi G, Bertin R, Dorigo P, Montopoli M, Caparrotta L (2011) Endothelium-independent vasorelaxation by ticlopidine and clopidogrel in rat caudal artery. J Pharm Pharmacol 63:1056\u20131062. https:\/\/doi.org\/10.1111\/j.2042-7158.2011.01313.x","journal-title":"J Pharm Pharmacol"},{"key":"9876_CR100","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1258\/rsmvasc.13.1.43","volume":"13","author":"SL Bledsoe","year":"2005","unstructured":"Bledsoe SL, Brown AT, Davis JA, Chen H, Eidt JF, Moursi MM (2005) Effect of clopidogrel on platelet aggregation and intimal hyperplasia following carotid endarterectomy in the rat. Vascular 13:43\u201349. https:\/\/doi.org\/10.1258\/rsmvasc.13.1.43","journal-title":"Vascular"},{"key":"9876_CR101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/153857440604000107","volume":"40","author":"SL Bledsoe","year":"2006","unstructured":"Bledsoe SL, Barr JC, Fitzgerald RT, Brown AT, Faas FH, Eidt JF et al (2006) Pravastatin and clopidogrel combined inhibit intimal hyperplasia in a rat carotid endarterectomy model. Vasc Endovascular Surg 40:49\u201357. https:\/\/doi.org\/10.1177\/153857440604000107","journal-title":"Vasc Endovascular Surg"},{"key":"9876_CR102","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/sj.bjp.0703386","volume":"130","author":"KS Erga","year":"2000","unstructured":"Erga KS, Seubert CN, Liang HX, Wu L, Shryock JC, Belardinelli L (2000) Role of A(2A)-adenosine receptor activation for ATP-mediated coronary vasodilation in guinea-pig isolated heart. Br J Pharmacol 130:1065\u20131075. https:\/\/doi.org\/10.1038\/sj.bjp.0703386","journal-title":"Br J Pharmacol"},{"issue":"2078","key":"9876_CR103","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.wneu.2015.08.016","volume":"84","author":"BD Killory","year":"2015","unstructured":"Killory BD, Kilbourn KJ, Ollenschleger M (2015) A Novel use of direct platelet application during surgery for clopidogrel-associated intracerebral hemorrhage. World Neurosurg 84(2078):e1-4. https:\/\/doi.org\/10.1016\/j.wneu.2015.08.016","journal-title":"World Neurosurg"},{"key":"9876_CR104","first-page":"136","volume":"2","author":"SM Cordina","year":"2009","unstructured":"Cordina SM, Hassan AE, Ezzeddine MA (2009) Prevalence and clinical characteristics of intracerebral hemorrhages associated with clopidogrel. J Vasc Interv Neurol 2:136\u2013138","journal-title":"J Vasc Interv Neurol"},{"key":"9876_CR105","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.ijcard.2013.06.135","volume":"168","author":"JJ DiNicolantonio","year":"2013","unstructured":"DiNicolantonio JJ, D\u2019Ascenzo F, Tomek A, Chatterjee S, Niazi AK, Biondi-Zoccai G (2013) Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. Int J Cardiol 168:1739\u20131744. https:\/\/doi.org\/10.1016\/j.ijcard.2013.06.135","journal-title":"Int J Cardiol"},{"key":"9876_CR106","doi-asserted-by":"publisher","first-page":"e000359","DOI":"10.1161\/JAHA.113.000359","volume":"2","author":"SKL Darweesh","year":"2013","unstructured":"Darweesh SKL, Leening MJG, Akoudad S, Loth DW, Hofman A, Ikram MA et al (2013) Clopidogrel use is associated with an increased prevalence of cerebral microbleeds in a stroke-free population: the Rotterdam study. J Am Heart Assoc 2:e000359. https:\/\/doi.org\/10.1161\/JAHA.113.000359","journal-title":"J Am Heart Assoc"},{"key":"9876_CR107","doi-asserted-by":"publisher","first-page":"e14685","DOI":"10.1097\/MD.0000000000014685","volume":"98","author":"L Ge","year":"2019","unstructured":"Ge L, Ouyang X, Ban C, Yu H, Wu Q, Wu H et al (2019) Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel. Medicine (Baltimore) 98:e14685. https:\/\/doi.org\/10.1097\/MD.0000000000014685","journal-title":"Medicine (Baltimore)"},{"key":"9876_CR108","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archneurol.2009.42","volume":"66","author":"MW Vernooij","year":"2009","unstructured":"Vernooij MW, Haag MDM, van der Lugt A, Hofman A, Krestin GP, Stricker BH et al (2009) Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan study. Arch Neurol 66:714\u2013720. https:\/\/doi.org\/10.1001\/archneurol.2009.42","journal-title":"Arch Neurol"},{"key":"9876_CR109","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1161\/STROKEAHA.109.572594","volume":"41","author":"CE Lovelock","year":"2010","unstructured":"Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CLM, Edinburgh Stroke Study Group et al (2010) Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 41:1222\u20131228. https:\/\/doi.org\/10.1161\/STROKEAHA.109.572594","journal-title":"Stroke"},{"key":"9876_CR110","doi-asserted-by":"publisher","first-page":"73","DOI":"10.12779\/dnd.2018.17.3.73","volume":"17","author":"J Lee","year":"2018","unstructured":"Lee J, Sohn EH, Oh E, Lee AY (2018) Characteristics of cerebral microbleeds. Dement Neurocognitive Disord 17:73\u201382. https:\/\/doi.org\/10.12779\/dnd.2018.17.3.73","journal-title":"Dement Neurocognitive Disord"},{"key":"9876_CR111","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.jacc.2021.07.048","volume":"78","author":"ACT Ha","year":"2021","unstructured":"Ha ACT, Bhatt DL, Rutka JT, Johnston SC, Mazer CD, Verma S (2021) Intracranial hemorrhage during dual antiplatelet therapy: JACC review topic of the week. J Am Coll Cardiol 78:1372\u20131384. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.048","journal-title":"J Am Coll Cardiol"},{"key":"9876_CR112","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354\u2013362. https:\/\/doi.org\/10.1056\/NEJMoa0809171","journal-title":"N Engl J Med"},{"key":"9876_CR113","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.thromres.2021.01.026","volume":"200","author":"L Crescence","year":"2021","unstructured":"Crescence L, Darbousset R, Caroff E, Hubler F, Riederer MA, Panicot-Dubois L et al (2021) Selatogrel, a reversible P2Y12 receptor antagonist, has reduced off-target interference with haemostatic factors in a mouse thrombosis model. Thromb Res 200:133\u2013140. https:\/\/doi.org\/10.1016\/j.thromres.2021.01.026","journal-title":"Thromb Res"},{"key":"9876_CR114","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1124\/jpet.110.178574","volume":"338","author":"P Andr\u00e9","year":"2011","unstructured":"Andr\u00e9 P, DeGuzman F, Haberstock-Debic H, Mills S, Pak Y, Inagaki M et al (2011) Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding. J Pharmacol Exp Ther 338:22\u201330. https:\/\/doi.org\/10.1124\/jpet.110.178574","journal-title":"J Pharmacol Exp Ther"},{"key":"9876_CR115","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1124\/mol.112.084392","volume":"83","author":"H Zhang","year":"2013","unstructured":"Zhang H, Lauver DA, Lucchesi BR, Hollenberg PF (2013) Formation, reactivity, and antiplatelet activity of mixed disulfide conjugates of clopidogrel. Mol Pharmacol 83:848\u2013856. https:\/\/doi.org\/10.1124\/mol.112.084392","journal-title":"Mol Pharmacol"},{"key":"9876_CR116","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1124\/jpet.116.236034","volume":"359","author":"H Zhang","year":"2016","unstructured":"Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE et al (2016) Significant improvement of antithrombotic responses to clopidogrel by use of a novel conjugate as revealed in an arterial model of thrombosis. J Pharmacol Exp Ther 359:11\u201317. https:\/\/doi.org\/10.1124\/jpet.116.236034","journal-title":"J Pharmacol Exp Ther"},{"key":"9876_CR117","doi-asserted-by":"publisher","first-page":"e00509","DOI":"10.1002\/prp2.509","volume":"7","author":"DA Lauver","year":"2019","unstructured":"Lauver DA, Kuszynski DS, Christian BD, Bernard MP, Teuber JP, Markham BE et al (2019) DT-678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y12 antagonists. Pharmacol Res Perspect 7:e00509. https:\/\/doi.org\/10.1002\/prp2.509","journal-title":"Pharmacol Res Perspect"},{"key":"9876_CR118","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1038\/s41467-018-06373-0","volume":"9","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Romero EL, Ren X, Sanca AJ, Du C, Liu C et al (2018) Clopidogrel as a donor probe and thioenol derivatives as flexible promoieties for enabling H2S biomedicine. Nat Commun 9:3952. https:\/\/doi.org\/10.1038\/s41467-018-06373-0","journal-title":"Nat Commun"},{"key":"9876_CR119","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cca.2014.10.037","volume":"439","author":"B Olas","year":"2015","unstructured":"Olas B (2015) Hydrogen sulfide in signaling pathways. Clin Chim Acta 439:212\u2013218. https:\/\/doi.org\/10.1016\/j.cca.2014.10.037","journal-title":"Clin Chim Acta"},{"key":"9876_CR120","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1160\/TH10-09-0582","volume":"105","author":"G Tuffal","year":"2011","unstructured":"Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N et al (2011) An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105:696\u2013705. https:\/\/doi.org\/10.1160\/TH10-09-0582","journal-title":"Thromb Haemost"},{"key":"9876_CR121","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1021\/tx300460k","volume":"26","author":"Y Zhu","year":"2013","unstructured":"Zhu Y, Zhou J (2013) In vitro biotransformation studies of 2-oxo-clopidogrel: multiple thiolactone ring-opening pathways further attenuate prodrug activation. Chem Res Toxicol 26:179\u2013190. https:\/\/doi.org\/10.1021\/tx300460k","journal-title":"Chem Res Toxicol"},{"key":"9876_CR122","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1124\/dmd.30.11.1288","volume":"30","author":"J-M Pereillo","year":"2002","unstructured":"Pereillo J-M, Maftouh M, Andrieu A, Uzabiaga M-F, Fedeli O, Savi P et al (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288\u20131295. https:\/\/doi.org\/10.1124\/dmd.30.11.1288","journal-title":"Drug Metab Dispos"},{"key":"9876_CR123","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1021\/ml3002067","volume":"3","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Zhou J (2012) Identification of the significant involvement and mechanistic role of CYP3A4\/5 in clopidogrel bioactivation. ACS Med Chem Lett 3:844\u2013849. https:\/\/doi.org\/10.1021\/ml3002067","journal-title":"ACS Med Chem Lett"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-022-09876-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-022-09876-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-022-09876-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:16:30Z","timestamp":1660896990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-022-09876-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["9876"],"URL":"https:\/\/doi.org\/10.1007\/s11302-022-09876-0","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author 1 declares that he\/she has no conflict of interest.Author 2 declares that he\/she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}